Quantifying muscle strength, size, and neuromuscular activation in adolescent and young adult survivors of musculoskeletal sarcoma: Identifying correlates and responses to functional strengthening.
Biomechanics
Muscle architecture
Oncology
Pediatrics
Physiology
Rehabilitation science
Journal
The Knee
ISSN: 1873-5800
Titre abrégé: Knee
Pays: Netherlands
ID NLM: 9430798
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
26
10
2022
accepted:
29
11
2022
pmc-release:
01
01
2024
pubmed:
19
12
2022
medline:
4
2
2023
entrez:
18
12
2022
Statut:
ppublish
Résumé
Medical and surgical treatment for musculoskeletal sarcoma (MSS) place survivors at risk for impairments in muscle properties including muscle strength, muscle size, and neuromuscular activation. The purpose of this study was to explore muscle properties, gross motor performance, and quality of life (QoL) and the changes in response to a 6-week functional strengthening intervention (PT-STRONG) in MSS survivors of childhood cancer (CCS). Eight lower extremity MSS CCS (13-23 years old) performed baseline testing and three completed PT-STRONG. Participants completed measurements of knee extension strength using handheld dynamometry, vastus lateralis (VL) and rectus femoris (RF) muscle thickness using ultrasonography at rest, and neuromuscular activation using electromyography during strength testing and a step-up task. Participants also completed gross motor and QoL assessments. Compared with the non-surgical limb, MSS CCS had lower surgical limb knee extension strength, VL muscle thickness, and RF step-up muscle rate of activation (RoA). Compared with normative values, MSS CCS had decreased bilateral knee extension strength, gross motor performance, and physical QoL. Positive correlations among muscle strength, muscle thickness, and gross motor performance were identified. After PT-STRONG, MSS CCS had improvements in VL muscle thickness, VL and RF RoA duing step-up, gross motor performance, and physical QoL. Positive association between larger muscle thickness with greater knee extension strength, and higher knee extension strength with better gross motor performance indicate that comprehensive physical therapy assessment and interventions that identify and target impairments in muscle properties to guide clinical decision making should be considered for MSS CCS into survivorship.
Sections du résumé
BACKGROUND
BACKGROUND
Medical and surgical treatment for musculoskeletal sarcoma (MSS) place survivors at risk for impairments in muscle properties including muscle strength, muscle size, and neuromuscular activation. The purpose of this study was to explore muscle properties, gross motor performance, and quality of life (QoL) and the changes in response to a 6-week functional strengthening intervention (PT-STRONG) in MSS survivors of childhood cancer (CCS).
METHODS
METHODS
Eight lower extremity MSS CCS (13-23 years old) performed baseline testing and three completed PT-STRONG. Participants completed measurements of knee extension strength using handheld dynamometry, vastus lateralis (VL) and rectus femoris (RF) muscle thickness using ultrasonography at rest, and neuromuscular activation using electromyography during strength testing and a step-up task. Participants also completed gross motor and QoL assessments.
RESULTS
RESULTS
Compared with the non-surgical limb, MSS CCS had lower surgical limb knee extension strength, VL muscle thickness, and RF step-up muscle rate of activation (RoA). Compared with normative values, MSS CCS had decreased bilateral knee extension strength, gross motor performance, and physical QoL. Positive correlations among muscle strength, muscle thickness, and gross motor performance were identified. After PT-STRONG, MSS CCS had improvements in VL muscle thickness, VL and RF RoA duing step-up, gross motor performance, and physical QoL.
CONCLUSIONS
CONCLUSIONS
Positive association between larger muscle thickness with greater knee extension strength, and higher knee extension strength with better gross motor performance indicate that comprehensive physical therapy assessment and interventions that identify and target impairments in muscle properties to guide clinical decision making should be considered for MSS CCS into survivorship.
Identifiants
pubmed: 36529045
pii: S0968-0160(22)00208-3
doi: 10.1016/j.knee.2022.11.024
pmc: PMC9898163
mid: NIHMS1858833
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-282Subventions
Organisme : NIAMS NIH HHS
ID : T32 AR007592
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Neuromuscul Disord. 2001 Jul;11(5):441-6
pubmed: 11404114
J Rehabil Med. 2006 Jan;38(1):57-64
pubmed: 16548089
Gait Posture. 2014 Sep;40(4):622-7
pubmed: 25103777
Dev Med Child Neurol. 2008 Mar;50(3):199-203
pubmed: 18215191
Int J Cancer. 2020 Aug 1;147(3):847-855
pubmed: 31800093
Disabil Rehabil. 2006 Jan 15;28(1):61-6
pubmed: 16393834
Knee. 2009 Oct;16(5):405-8
pubmed: 19269182
Pediatr Blood Cancer. 2013 Jun;60(6):1009-15
pubmed: 23255238
Front Pediatr. 2022 May 11;10:891650
pubmed: 35633967
Pediatr Phys Ther. 2012 Fall;24(3):224-30
pubmed: 22735469
Arch Phys Med Rehabil. 2006 Aug;87(8):1091-9
pubmed: 16876555
Children (Basel). 2015;2(1):1-36
pubmed: 25692094
Pediatr Blood Cancer. 2007 Aug;49(2):183-9
pubmed: 16779807
J Electromyogr Kinesiol. 2014 Aug;24(4):502-7
pubmed: 24794866
J Electromyogr Kinesiol. 2010 Jun;20(3):502-7
pubmed: 19560372
J Electromyogr Kinesiol. 2002 Oct;12(5):399-406
pubmed: 12223173
Pediatr Blood Cancer. 2010 May;54(5):738-45
pubmed: 20127850
J Am Acad Orthop Surg. 2017 Mar;25(3):204-213
pubmed: 28195984
J Cancer Surviv. 2017 Feb;11(1):1-12
pubmed: 27262580
Br J Cancer. 2004 Nov 29;91(11):1858-65
pubmed: 15534610
BMC Geriatr. 2007 Jul 04;7:17
pubmed: 17610735
Front Neurol. 2017 Dec 22;8:699
pubmed: 29312124
Pediatr Blood Cancer. 2004 Feb;42(2):127-33
pubmed: 14752875
Antioxid Redox Signal. 2011 Nov 1;15(9):2543-63
pubmed: 21457105
J Appl Physiol (1985). 2003 Mar;94(3):983-90
pubmed: 12571130
Pediatr Blood Cancer. 2007 Dec;49(7):964-9
pubmed: 16921515
J Pediatr Rehabil Med. 2021;14(3):415-423
pubmed: 33935120
JAMA. 2003 Sep 24;290(12):1583-92
pubmed: 14506117
Cancer. 2011 Feb 1;117(3):625-34
pubmed: 20922787
Ann Intern Med. 2005 Nov 1;143(9):639-47
pubmed: 16263886
Osteoporos Sarcopenia. 2019 Sep;5(3):94-101
pubmed: 31728427
Electromyogr Clin Neurophysiol. 1985 Mar-Apr;25(2-3):135-49
pubmed: 3987606
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Phys Ther. 2010 Mar;90(3):438-49
pubmed: 20075147
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Pediatr Phys Ther. 2004 Summer;16(2):90-8
pubmed: 17057533
Phys Ther. 2006 May;86(5):735-43
pubmed: 16649896
Pediatr Phys Ther. 2016 Spring;28(1):16-22
pubmed: 27088678
Front Pediatr. 2020 Jun 16;8:292
pubmed: 32612962
Br J Cancer. 2009 Jan 27;100(2):311-4
pubmed: 19165199
Pediatr Blood Cancer. 2012 Jun;58(6):978-85
pubmed: 21990185
Support Care Cancer. 2013 Jun;21(6):1629-36
pubmed: 23292667
Pediatr Phys Ther. 2006 Winter;18(4):238-44
pubmed: 17108796
Am J Surg Pathol. 2018 May;42(5):604-615
pubmed: 29300189
Rehabil Oncol. 2017 Jan;35(1):38-45
pubmed: 28948112
Eur J Cancer Care (Engl). 2017 Jul;26(4):
pubmed: 28657211
Rev Paul Pediatr. 2013 Sep;31(3):377-83
pubmed: 24142322
J Orthop Sports Phys Ther. 1998 Aug;28(2):97-104
pubmed: 9699159
Phys Ther. 2010 Nov;90(11):1619-30
pubmed: 20847035
J Electromyogr Kinesiol. 2013 Dec;23(6):1485-93
pubmed: 23953763
J Strength Cond Res. 2013 Nov;27(11):3053-9
pubmed: 23439346
Arch Phys Med Rehabil. 2009 Jun;90(6):1039-47
pubmed: 19480882
Hematol Oncol Stem Cell Ther. 2013 Sep-Dec;6(3-4):105-11
pubmed: 24161605
Gait Posture. 2009 Nov;30(4):547-51
pubmed: 19747830
Curr Opin Pediatr. 2009 Jun;21(3):365-72
pubmed: 19421061
Front Pediatr. 2020 Jun 05;8:243
pubmed: 32582585
J Surg Oncol. 2011 Mar 1;103(3):276-82
pubmed: 21337557
Arch Phys Med Rehabil. 2013 Jun;94(6):1062-73
pubmed: 23380347
Dev Med Child Neurol. 2005 Aug;47(8):518-24
pubmed: 16108451
BMC Musculoskelet Disord. 2018 Sep 27;19(1):350
pubmed: 30261863
Front Physiol. 2021 Oct 14;12:744153
pubmed: 34721067
Phys Occup Ther Pediatr. 2021;41(5):540-554
pubmed: 33563044
J Orthop Res. 1998 Jan;16(1):136-43
pubmed: 9565086
Dev Med Child Neurol. 2009 Oct;51(10):800-6
pubmed: 19459913
J Phys Ther Sci. 2015 Mar;27(3):851-4
pubmed: 25931745